GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » E10

RGLS (Regulus Therapeutics) E10 : $-76.26 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Regulus Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Regulus Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.210. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-76.26 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 51.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Regulus Therapeutics was 51.90% per year. The lowest was 51.90% per year. And the median was 51.90% per year.

As of today (2025-03-04), Regulus Therapeutics's current stock price is $1.355. Regulus Therapeutics's E10 for the quarter that ended in Sep. 2024 was $-76.26. Regulus Therapeutics's Shiller PE Ratio of today is .


Regulus Therapeutics E10 Historical Data

The historical data trend for Regulus Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics E10 Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -782.62 -668.82 -93.17 -87.30

Regulus Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -89.30 -87.30 -84.16 -80.09 -76.26

Competitive Comparison of Regulus Therapeutics's E10

For the Biotechnology subindustry, Regulus Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regulus Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Shiller PE Ratio falls into.



Regulus Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regulus Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.21/133.0289*133.0289
=-0.210

Current CPI (Sep. 2024) = 133.0289.

Regulus Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -56.400 99.070 -75.733
201503 -34.800 99.621 -46.470
201506 -49.200 100.684 -65.006
201509 -30.000 100.392 -39.753
201512 -16.800 99.792 -22.395
201603 -48.000 100.470 -63.555
201606 -48.000 101.688 -62.794
201609 -44.400 101.861 -57.986
201612 -45.600 101.863 -59.552
201703 -45.600 102.862 -58.973
201706 -49.200 103.349 -63.329
201709 -21.100 104.136 -26.954
201712 -16.800 104.011 -21.487
201803 -18.500 105.290 -23.374
201806 -15.900 106.317 -19.895
201809 -11.800 106.507 -14.738
201812 -9.800 105.998 -12.299
201903 -3.100 107.251 -3.845
201906 -3.000 108.070 -3.693
201909 -2.600 108.329 -3.193
201912 -2.300 108.420 -2.822
202003 -2.500 108.902 -3.054
202006 -2.300 108.767 -2.813
202009 -0.400 109.815 -0.485
202012 -0.300 109.897 -0.363
202103 -0.800 111.754 -0.952
202106 -0.780 114.631 -0.905
202109 -0.990 115.734 -1.138
202112 -0.700 117.630 -0.792
202203 -0.460 121.301 -0.504
202206 -0.500 125.017 -0.532
202209 -0.500 125.227 -0.531
202212 -0.400 125.222 -0.425
202303 -0.420 127.348 -0.439
202306 -0.370 128.729 -0.382
202309 -0.400 129.860 -0.410
202312 -0.390 129.419 -0.401
202403 -0.290 131.776 -0.293
202406 -0.170 132.554 -0.171
202409 -0.210 133.029 -0.210

Add all the adjusted EPS together and divide 10 will get our e10.


Regulus Therapeutics  (NAS:RGLS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Regulus Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Regulus Therapeutics Business Description

Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Executives
David Baltimore director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Joseph P Hagan officer: Chief Operating Officer 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Ray Aker officer: Sr. VP & General Counsel C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Crispina Calsada officer: Chief Financial Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Preston Klassen officer: President & Head of R & D 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kathryn J Collier director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Denis Drygin officer: Chief Scientific Officer 10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Alice Shih-hou Huang director 10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Growth Equity Opportunities V, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Scott D Sandell 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025